

## Block Listing SIX MONTHLY RETURN

**November 23, 2016** - Shire plc (LSE: SHP, NASDAQ: SHPG)

Name of <i>applicant</i> :		Shire plc	
Name of scheme:		Shire Sharesave Scheme	
Period of return:	From:	May 23, 2016	To: November 22, 2016
Balance of unallotted securities under scheme(s) from previous return:		184,913	
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil	
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		302	
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		184,611	

Name of <i>applicant</i> :		Shire plc	
Name of scheme:		Shire Portfolio Share Plan	
Period of return:	From:	May 23, 2016	To: November 22, 2016
Balance of unallotted securities under scheme(s) from previous return:		1,204,351	
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil	
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		434,736	
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		769,615	

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Employee Stock Purchase Plan		
Period of return:	From:	May 23, 2016	To:	November 22, 2016
Balance of unallotted securities under scheme(s) from previous return:		244,451		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		394		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		244,057		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Long Term Incentive Plan 2015		
Period of return:	From:	May 23, 2016	To:	November 22, 2016
Balance of unallotted securities under scheme(s) from previous return:		2,955,872		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		119,460		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		2,836,412		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Global Employee Stock Purchase Plan		
Period of return:	From:	May 23, 2016	To:	November 22, 2016
Balance of unallotted securities under scheme(s) from previous return:		1,999,969		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		395,726		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		1,604,243		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Baxalta Exchange Awards		
Period of return:	From:	June 15, 2016	To:	November 22, 2016
Balance of unallotted securities under scheme(s) from previous return:		N/A		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		25,000,000		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		4,511,796		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		20,488,204		

Name of contact:	Sarah Rixon, Company Secretarial Assistant
Telephone number of contact:	01256 894000

**For further information please contact:**

**Investor Relations**

Sarah Elton-Farr	<a href="mailto:seltonfarr@shire.com">seltonfarr@shire.com</a>	+44 1256 894157
Ian Karp	<a href="mailto:ikarp@shire.com">ikarp@shire.com</a>	+1 781 482 9018
Robert Coates	<a href="mailto:rcoates@shire.com">rcoates@shire.com</a>	+44 1256 894874

**Media**

Lisa Adler	<a href="mailto:lisa.adler@shire.com">lisa.adler@shire.com</a>	+1-617 588 8607
Debbi Ford	<a href="mailto:debbi.ford@shire.com">debbi.ford@shire.com</a>	+1 617 949 9083

**NOTES TO EDITORS**

**About Shire**

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

[www.shire.com](http://www.shire.com)